ITIH3

Across TCGA pan-cancer cohorts, ITIH3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ITIH3 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ITIH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITIH3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, OV, and COAD are the cancer types where ITIH3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.102	0.688	<.001	36	view →
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
COAD	OS	Median	II,III,IV	0.111	0.851	<.001	8	view →
UCEC	DFS	Median	All	0.932	0.618	.024	8	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
PAAD	DFS	Median	II,III,IV	0.160	0.437	.036	6	view →
BLCA	DFS	Median	IV	0.090	0.476	.011	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ITIH3–UCS (OS)

Open the UCS breakdown →